EMD Serono, a division of Merck KGaA, reached a drug pricing deal with the Trump administration that will lower the cost of the company’s fertility treatments in exchange for tariff reprieve and expedited regulatory review of a product being brought to the US. Pharma’s pricing agreements with the government suggest they were far more worried about tariffs on US drug imports than they admitted in earnings calls or media interviews. Large drugmakers that are thinking through their own versions of deals will need to weigh their proposed product discounts against tariff exposure if they choose not to comply with the administration.
Americans’ trust in federal health agencies and political leaders continues to erode, but while many are confused about what to believe, they still want clearer guidance, per the latest Axios/Ipsos American Health Index. Federal agency staffing cuts, shifting vaccine guidance, and the glut of social media health information have fragmented Americans’ health trust. But trust hasn’t completely disappeared; it’s just gone local. Consumers still believe their doctors and families, creating an opening for healthcare and pharma brands to deliver clear, credible information through those trusted messengers.
Healthcare marketing faces unique challenges as skeptical consumers find it hard to trust much of the messaging sent their way.
Hims & Hers and GoodRx each moved into new categories of prescription drug sales. Hims and Hers is now offering care for menopause and perimenopause under its Hers brand, while GoodRx launched a subscription for men’s hair loss treatment. GoodRx is a new player in an expanding market of companies selling prescription drugs, but we think the company has staying power. GoodRx’s vast user base offers a cheaper, more efficient path to converting consumers into subscription members than other D2C healthcare competitors.
Nearly 4 in 10 (38%) US parents consider themselves supporters of the Make America Healthy Again (MAHA) movement, according to a recent KFF/The Washington Post survey. MAHA supporters and non-supporters hold distinct views on the importance and safety of vaccines and other children’s health issues. Pharma and food marketers should encourage open dialogue around the concerns expressed by MAHA proponents. Marketers need to reach parents who are MAHA supporters with transparent, evidence-based messaging—not lectures—on food and drug safety.
The FDA sent another batch of warning letters to direct-to-consumer pharma advertisers, adding healthcare professional marketing to its list of complaints. Marketers should prepare for more intense medical and legal review checks, but also expand beyond brand messaging rather than pullback on the key HCP prescriber audience.
OpenAI created an Expert Council on Well-Being and AI—a panel of eight behavioral and mental health specialists tasked to guide how AI tools like ChatGPT and Sora interact with users, per Ars Technica. CEO Sam Altman also announced on X that, “now that we have been able to mitigate the serious mental health issues and have new tools, we are going to be able to safely relax the restrictions in most cases.” OpenAI’s loosening guardrails shift responsibility to brands and users who must now share in the responsibility to define and enforce their own ethical boundaries.
Pharma brands are partnering with Reddit to engage with patients more directly, according to a panel discussion at last week’s Advertising Week New York event. Healthcare and pharma brands need to be on Reddit, where communities actively discuss wellness, medications, and medical services. However, healthcare and pharma marketers must avoid obvious promotions, and instead post information that can help people while conducting their own Q&As hosted by company leaders with medical credentials.
As pharma marketers and ad agencies begin to shift ad dollars from traditional linear to digital CTV, media buying is moving from programs and broad demo buys to data-driven audience targeting. Healthcare and pharma marketers have long relied on the broad reach and frequency of linear TV, but need to recognize the growing power of CTV. Marketers shouldn’t think of CTV as a replacement, but as a performance layer on top of linear’s scale and reach.
Lyra Health is debuting a generative AI (genAI) chatbot for mild to moderate mental health challenges like burnout, sleep or stress. AI chatbots for mental health will likely keep growing as consumers, especially younger generations, seek more affordable, lower-pressure alternatives to traditional in-person therapy. Lyra’s measured rollout shows how AI therapy could be deployed responsibly: limiting chatbot use to lower-risk mental health issues and emphasizing safety.
AstraZeneca reached a deal with the US government to lower prescription drug prices in exchange for a three-year tariff reprieve. If more Big Pharma deals with Trump mirror Pfizer’s and AstraZeneca’s, it signals the sector views the terms as favorable, since core revenue drivers remain largely untouched. Still, pricing pressure won’t subside anytime soon, with more drugs expected to be up for Medicare price negotiations. Big Pharma shouldn’t view these latest agreements as the end of the line, but rather as important learning moments for which drug pricing concessions will appease the administration.
Pharmacies and prescription drug discounter GoodRx are in talks with the Trump administration about joining its planned direct-to-consumer (D2C) prescription drug portal called TrumpRx. Pharmacy retailer and GoodRx participation could determine whether TrumpRx stays a niche effort or evolves into a consumer prescription drug marketplace. Pharma marketers joining the platform should build on existing pharmacy and GoodRx partnerships, and focus on creating consumer-friendly e-commerce and telehealth experiences.
Nearly all of healthcare professionals' (HCPs) medical content consumption is happening via digital channels and sources, according to a July 2025 M3 MI study. Healthcare and pharma brands have recognized that they must meet time-strapped HCPs on online channels, many of which allow drug advertising. Drug and medical device marketers can deliver more effective and personalized information to clinicians once they gain a better understanding of their preferences for consuming online medical content.
Pharma linear TV ad spending totaled $1.25 billion in Q3, with prescription drug commercials taking the leading share of national TV ad spending for the quarter, according to iSpot.tv. Pharma marketers are reallocating more of their budgets toward digital—especially connected TV (CTV) and social media—for more precise targeting and measurement gains. However, linear TV is still important for Big Pharma, especially for mainstream events like live sports, to drive board awareness of common health conditions. We expect linear TV’s scale, trust, and cultural relevance will keep it in the mix for the foreseeable future.
Novo Nordisk lost its federal appeals court challenge of the prescription drug price negotiation program in the Biden-era Inflation Reduction Act (IRA) prescription drug price negotiation program, which could open the door for even more price checks. We see a path where the current administration revamps, or simply rebrands, IRA price negotiations as CMS negotiations to save taxpayer money and help consumers. Brands under pressure to drop prices through the IRA and executive orders should continue those good–faith efforts but also encourage the administration to put the same pressure on insurance companies and pharmaceutical benefit managers to lower healthcare costs.
Most US consumers are already using digital tools for healthcare purposes, but three-quarters would prefer more personalized solutions, per a new Harris Poll sponsored by Verily. Healthcare marketers and brands need to use generative AI (genAI) tools, like remote monitoring, predictive analysis, and chatbots, to deliver personalized consumer experiences.
The Trump administration will opt against imposing tariffs on generic drug imports, according to The Wall Street Journal. Trump’s reprieve for generic drugmakers signals that brand-name medication imports won’t be spared from tariffs. Big Pharma brands that want to avoid Trump tariffs will have to follow Pfizer’s lead in striking deals with the administration. That will include lowering prices and cutting out industry middlemen like PBMs and insurers for some drugs and immediately starting to build more US manufacturing capability.
Amazon Pharmacy will soon roll out kiosks at select One Medical locations in Los Angeles. One Medical patients will use the Amazon app to generate a QR code, which they scan at the kiosk to pick up and pay for prescriptions. The kiosk model highlights Amazon’s focus on accessibility, but it’s unlikely to shift the pharmacy market—at least for now. Still, brick-and-mortar pharmacies must recognize Amazon’s advantage: a customer-centric approach paired with online convenience.
Acting CDC Director Jim O’Neill wrote in a post on X that pharma manufacturers should make separate shots for measles, mumps, and rubella (MMR) instead of the current vaccine, which combines the three. Although people don’t have the option to break out the MMR vaccine into three doses, the administration’s rhetoric could drive more parents to skip or delay a needed treatment for their kids. Vaccine makers and pharma marketers must address criticism that the combined MMR shot is unsafe for children by emphasizing how contagious measles is and the risks of lower vaccination rates when three appointments are required.